Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5692352 | 0.80 | CES2 (0.34) | DAOCES2CES1GSK3BSMN1; SMN2 | |
| SCHEMBL340904 | 0.79 | GABBR2 (0.67) | GABBR2GABBR1DAOKMT2A | |
| SCHEMBL27697147 | 0.79 | GABBR2 (0.66) | GABBR2GABBR1DAOGSK3BKMT2A | |
| SCHEMBL1520622 | 0.79 | ALOX5 (0.46) | GABBR2GABBR1DAOFFAR1SMN1; SMN2 | |
| SCHEMBL4240529 | 0.76 | DAO (0.45) | DAOCES2CES1GSK3BKMT2A | |
| SCHEMBL20546457 | 0.75 | FFAR1 (0.59) | GABBR2GABBR1FFAR1SMN1; SMN2MAPK1 | |
| SCHEMBL20546458 | 0.75 | FFAR1 (0.59) | GABBR2GABBR1FFAR1SMN1; SMN2MAPK1 | |
| SCHEMBL23695520 | 0.73 | SLC6A4 (0.34) | CES2CES1GSK3BMAPK1KMT2A | |
| SCHEMBL3465870 | 0.73 | SLC6A4 (0.34) | CES2CES1GSK3BMAPK1KMT2A | |
| SCHEMBL15156804 | 0.73 | SLC6A4 (0.34) | CES2CES1GSK3BMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124654-A1 | Aryl and Heteroaryl Compounds, Compositions, Methods of Use | TRANSTECH PHARMA, INC. | 2009-05-14 | — | — | US | disclosed |
| CN-101137650-A | 2- [ isoquinoline-S-carbonyl ] amino ] -propionic acid derivatives as inhibitors of factors XI and IX for the treatment of thrombosis | TRANSTECH PHARMA INC (US) | 2008-03-05 | — | — | CN | disclosed |
| EP-1888566-A1 | 2-[(ISOQUINOLIN-3-CARBONYL)AMINO]-PROPIONIC ACID DERIVATIVES AS INHIBITORS OF FACTORS XI AND IX FOR THE TREATMENT OF THROMBOSIS | Transtech Pharma, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070254916-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | MJALLI ADNAN M | 2007-11-01 | — | — | US | disclosed |
| US-7208601-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, LLC | 2007-04-24 | — | — | US | disclosed |
| WO-2006093823-A9 | 2- [ ISOQUINOLIN-S - CARBONYL ) AMINO] -PROPIONIC ACID DERIVATIVES AS INHIBITORS OF FACTORS XI AND IX FOR THE TREATMENT OF THROMBOSIS | TRANSTECH PHARMA INC (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006093823-A1 | 2- [ ISOQUINOLIN-S - CARBONYL ) AMINO] -PROPIONIC ACID DERIVATIVES AS INHIBITORS OF FACTORS XI AND IX FOR THE TREATMENT OF THROMBOSIS | TRANSTECH PHARMA, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20050171148-A1 | Aryl and heteroaryl compounds, compositions, methods of use | TRANSTECH PHARMA, LLC | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124654-A1 | Aryl and Heteroaryl Compounds, Compositions, Methods of Use | F3, F12, CFH | GABBR2 545/4885GABBR1 467/4885DAO 83/4885 |
| US-20070254916-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F9, F3 | GABBR2 360/4885GABBR1 411/4885DAO 188/4885 |
| US-20050171148-A1 | Aryl and heteroaryl compounds, compositions, methods of use | TFPI, F3, F2 | GABBR2 384/4885GABBR1 463/4885DAO 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.